Navigation Links
AVI BioPharma Reports Positive Pre-Clinical Influenza Data

PORTLAND, Ore.--(BUSINESS WIRE)--May 1, 2007 - AVI BioPharma, Inc. (Nasdaq:AVII) and collaborators presented pre-clinical data demonstrating effectiveness of NEUGENE(R) antisense compounds against seasonal influenza A virus in mice. Thomas G. Voss, Ph.D., assistant professor, Department of Microbiology and Immunology, Tulane University School of Medicine, presented the data in poster form at the 20th International Conference on Antiviral Research on April 30, 2007.

In experiments sponsored by AVI and conducted at Tulane University School of Medicine and the United States Army Medical Research Institute for Infectious Diseases (USAMRIID), mice were pre-treated with antisense phosphorodiamidate morpholino oligomers (PMOs), and then infected with two different strains of influenza A (H3N2 and H1N1). Treated mice showed significantly reduced clinical signs (weight loss) and increased survival compared to control treated and untreated mice. In addition, PMO-treated mice showed significantly reduced viral titer (to below limit of detection) in comparison to untreated mice. Histological examination of the lungs showed that treated mice had reduced pathology when examined for infiltrating cells or alveolar damage.

"These data, in combination with other pre-clinical research, reinforce our belief that NEUGENE antisense compounds are potentially well-suited to treating seasonal influenza A infections," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "Now that we have demonstrated efficacy against multiple strains of seasonal flu in this model, we intend to evaluate our compounds in additional animal models to test their potential efficacy against the H5N1 subtype of avian flu."

AVI's NEUGENE antisense drug development program against the influenza A virus targets genetic regions of the virus that are highly conserved across six viral subtypes that cause human diseas e. These include three subtypes that caused pandemics in the 20th century -- the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2) and the 1968 Hong Kong flu (H3N2) -- and three subtypes of avian flu that have been reported to cause disease in humans (H5N1, H7N7 and H9N2). AVI's potential treatment for seasonal influenza A will be made available to potential licensees.

About Influenza A Viruses

Influenza, or flu, is a contagious respiratory illness caused by influenza viruses. On average 5 percent to 20 percent of the U.S. population is infected with the flu each year. Influenza A virus is an enveloped negative-strand RNA virus, with eight genome segments that code for 10 proteins. Influenza strains are subtyped according to the antigenic and genetic nature of their surface glycoproteins: hemagglutinin (HA or H) and neuraminidase (NA or N). Fifteen H and nine N subtypes have been identified, with three associated with widespread human disease (H1N1, H2N2 and H3N2). In addition, several subtypes of avian influenza virus -- H5N1, H7N7 and H9N2 -- can infect and cause disease in humans.

The current influenza pandemic in birds throughout Asia, Eastern Europe and Turkey is caused by the H5N1 subtype. It is thought that co-infection of humans or certain animals (such as pigs) with both H1N1 and H5N1 can lead to a reassortment or recombination of viral particles, resulting in the emergence of a virus with dangerous public health properties, namely one to which the human population has no natural immunity and which has the ability to spread easily from person to person. It is believed that emergence of avian flu by this general mechanism may have led to the worldwide pandemics of 1918, 1957 and 1968.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is design ed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy. More information about AVI is available on the company's Web site at

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.


AVI Contact:
AVI BioPharma, Inc.
Michael Hubbard, 503-227-0554
Investor Contacts:
Lippert/Heilshorn & Associates Inc.
Jody Cain or Brandi Floberg, 310-691-7100
Press Contact:
Waggener Edstrom Worldwide
Bioscience and Healthcare Practice
Jenny Moede, 503-443-7000


Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
6. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
Post Your Comments:
(Date:10/13/2015)... Fla. , Oct. 13, 2015   Vigilant ... of solutions that aid in the early detection and ... has awarded Vigilant,s founder and CEO, Matthew H.J. ... Year Award, which recognizes an entrepreneur who has made ... life sciences industry in the leadership of ...
(Date:10/13/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a ... serving the pharmaceutical, biotechnology, and medical device industries, ... version of OncoWuXi, the first App in the ... and data on the go.  The OncoWuXi App ... to identify relevant tumor models for use in ...
(Date:10/13/2015)... 13, 2015   Happy Vitals ®, ... home testing kit for breast milk.  The ... an unparalleled, detailed assessment of the nutrition ... carbs and key vitamins—all charted over time ... health tracking.  In addition, Happy Vitals also offers ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood ... 2015. The research, which was conducted at the Dental Institute at King's College London ... between stress during pregnancy and future dental health in the child. For years, researchers ...
(Date:10/13/2015)... ... October 13, 2015 , ... Protein is essential to good health. ... bone, and blood. But how much protein does the average man need in order ... according to the October 2015 issue of Harvard Men's Health Watch . Most ...
(Date:10/13/2015)... Waycross, GA (PRWEB) , ... October 13, 2015 ... ... charitable nonprofit promoting the establishment of telemedicine programs in communities throughout Georgia, along ... (FTP) announce the collective schedule for their regional telehealth summits for Fall 2015. ...
(Date:10/13/2015)... ... 13, 2015 , ... According to an ESPN report published on ... teammate accidentally elbowed him in the left eye during the first day of practice ... of a series of setbacks, including a knee injury that has interfered with his ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an ongoing effort ... , a Southlake, Texas, child development and pediatric therapy center, is working with ... families about their options for receiving this kind of care for affected children. ...
Breaking Medicine News(10 mins):